
|Videos|December 5, 2016
The Benefits of Venetoclax in CLL
Author(s)Jeffrey Jones, MD, MPH
Jeffrey Jones, MD, MPH, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the benefits of venetoclax in chronic lymphocytic luekemia (CLL).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Pant on Managing the Safety Profile of Daraxonrasib in Pancreatic Cancer
2
FDA Approves Camizestrant Plus CDK4/6 Inhibitor for ESR1-Mutant Breast Cancer
3
Azacitidine-Venetoclax Beats Induction Chemo as Upfront AML Therapy
4
AUA/SUO Issue 2026 Update to Non–Muscle Invasive Bladder Cancer Guideline
5


































